Press Releases Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General ObesityMarch 25, 2026Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic DiseasesMarch 19, 2026Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in ObesityOctober 2, 2025Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal CancerApril 30, 2025Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer PatientsDecember 20, 2024Endevica Bio Drug Candidate Shows Promise for Alleviating Chemotherapy-Induced Anorexia and Weight Loss, Study ShowsNovember 12, 2024Endevica Bio drug candidate shows success in weight loss in new studyApril 23, 2024 In the News Preventing Weight Loss Is Key to a Successful Cancer TreatmentFebruary 19, 2025GLP-1s and Vanishing Muscle MassDecember 4, 2024As Obese, Overweight Population Grows in the U.S., More Treatment Options Are NeededNovember 22, 2024Cachexia Research Targeting the Brain Holds Significant PromiseSeptember 25, 2024
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General ObesityMarch 25, 2026
Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic DiseasesMarch 19, 2026
Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal CancerApril 30, 2025
Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer PatientsDecember 20, 2024
Endevica Bio Drug Candidate Shows Promise for Alleviating Chemotherapy-Induced Anorexia and Weight Loss, Study ShowsNovember 12, 2024
As Obese, Overweight Population Grows in the U.S., More Treatment Options Are NeededNovember 22, 2024
